Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion

Lara, Susana Herrera; Fernández-Fabrellas, Estrella; Samper, Gustavo Juan; Buades, J.; Andreu, Rafael; Moreno, Amparo Pinilla; Suárez-Varela, María Morales

doi:10.1007/s00408-018-0186-7

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Figure 3 depicted that the OS outcome following PSM was similar to that before PSM (56 pairs, p = 0.007). The OS of MPE‐NSCLC patients is short, and one of the most critical adverse factors for OS is a large lung mass 42 . The more superior survival of the DRT group might be attributed to thoracic tumor controlled continuously, reduction in thoracic tumor failure 39,43 and additional disease control after progression 20,44 .…”

Section: Discussionmentioning

confidence: 99%

“…The OS of MPE-NSCLC patients is short, and one of the most critical adverse factors for OS is a large lung mass. 42 The more superior survival of the DRT group might be attributed to thoracic tumor controlled continuously, reduction in thoracic tumor failure 39,43 and additional disease control after progression. 20,44 As reported in previous studies, the OS outcome was in keeping with stage IV NSCLC without MPE based on multimodal treatment, including thoracic tumor radiotherapy and targeted therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study

Li,

Hu,

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundEGFR‐mutant (EGFR‐M) and ALK‐positive (ALK‐P)are common in malignant pleural effusion (MPE) with metastatic non‐small‐cell lung cancer (NSCLC) (MPE‐NSCLC). The impact of thoracic tumor radiotherapy on survival in such patients remains unclear. We aimed to investigate whether thoracic tumor radiotherapy could improve overall survival (OS) in such patients.MethodsAccording to whether or not patients accepted thoracic tumor radiotherapy, 148 patients with EGFR‐M or ALK‐P MPE‐NSCLC treated with targeted therapy were classified into two groups: DT group without thoracic tumor radiotherapy and DRT group with thoracic tumor radiotherapy. Propensity score matching (PSM) was performed to balance clinical baseline characteristics. Overall survival was analyzed by Kaplan–Meier, compared by log‐rank test, and evaluated using Cox proportional hazards model.ResultsMedian survival time (MST) was 25 months versus 17 months in the DRT group and DT group. The OS rates at 1, 2, 3, 5 years in the DRT group and DT group were 75.0%, 52.8%, 26.8%, 11.1% and 64.5%, 28.4%, 9.2%, 1.8%, respectively (χ2 = 12.028, p = 0.001). Compared with DT group, the DRT group still had better survival after PSM (p = 0.007). Before and after PSM, factors associated with better OS through multivariable analysis were that thoracic tumor radiotherapy, radiotherapy, N0‐2, and ALK‐TKIs. Grades 4–5 radiation toxicities were not observed in patients; 8 (11.6%) and 7 (10.1%) out of the DRT group suffered from Grade 3 radiation esophagitis and radiation pneumonitis, respectively.ConclusionOur results for EGFR‐M or ALK‐P MPE‐NSCLC showed that thoracic tumor radiotherapy may be crucial factor in improving OS with acceptable toxicities. Potential biases should not be neglected: Further randomized controlled trials are necessary to confirm this result.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study

Li,

Hu,

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…In this method, appropriate positive and negative controls were used in cell analysis. [ 12 16 17 18 19 20 21 22 ]…”

Section: Methodsmentioning

confidence: 99%

“…Although pleuroscopy can determine the cause of pleural effusion with 95% accuracy, it is invasive and not available in most hospitals. [ 12 13 14 ]…”

Section: Introductionmentioning

confidence: 99%

Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion

Bakhtiari

Mehraban²,

Pourdowlat³

et al. 2022

J Family Med Prim Care

View full text Add to dashboard Cite

A BSTRACT Background: There are two main causes of exudative effusion including malignancy-induced effusion and tuberculosis. Considering that in reactive ejections, such as tuberculosis-induced effusion, the role of B lymphocytes and in the malignant effusion, the role of T lymphocytes are more important, in this study we analyzed the frequency of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON in the pleural and serum samples of patients with exudative lymphocytic-dominant effusion. Methods: In total, 73 patients were enrolled in the study by exudative lymphocyte effusion, and finally, 63 patients had definite diagnoses. The patients were sorted into three groups including malignant, tuberculosis, and none. The sample of blood plasma and pleural effusion were collected and CD markers were analyzed using flow cytometry. Results: The mean age in the malignancy and tuberculous (TB) groups was 63.16 ± 12 and 52.15 ± 22.62, respectively. There was no significant difference in the frequency of CD8, CD4, and CD16-56 cells in blood samples of patients with tuberculosis and malignancy. Compared to those with tuberculosis, the percentage of CD64 cells was significantly higher in patients with tuberculosis than in malignant subjects. Moreover, a comparison of the frequency of cells with CD8, CD4, CD19, CD64, CD16-56, and CD14 markers in pleural samples showed no significant difference between groups. Other inflammatory factors were also investigated. The erythrocyte sedimentation rate (ESR) value for tuberculosis patients was significantly higher than malignancy. Also, QuantiFERON was positive in 14.3% of malignant patients, and 62.5% of patients with TB, which had a significant difference. Conclusion: Considering that there are many confounding variables in the study, such as previous medications, subtypes of Mycobacterium , and race of patients conducting studies in different groups and performing data mining for using a set of parameters can be used to detect the exact diagnosis.

show abstract

“…Estatísticas norte-americanas antigas já apresentavam o significativo número de mais de 1.000.000 casos novos de derrame pleural/ano, e destes, cerca de 200.000 estavam associados à doença maligna 1 . Mesmo com estes índices já elevados, expectativa é de um aumento de 5% ao ano nestes dados 2 .…”

Section: Resultsunclassified

Influência da progressão da neoplasia pleural no resultado da pleurodese em camundongos

Sabbion¹

View full text Add to dashboard Cite

show abstract

Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion

Cited by 4 publications

References 24 publications

Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study

Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study

Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion

Influência da progressão da neoplasia pleural no resultado da pleurodese em camundongos

Contact Info

Product

Resources

About